licensing

With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
BioPharma Dive
Fri, 08/9/24 - 11:55 am
biotech
licensing
Top biotech licensing deals of Q1 2023
BioSpace
Thu, 03/30/23 - 11:03 am
biotech
licensing
Moderna Therapeutics
CytomX
Voyager Therapeutics
Neurocrine Biosciences
Kronos Bio
Genentech
Karuna Therapeutics
Goldfinch Bio
Roche deal fails to Repare the licensing scene
EP Vantage
Tue, 06/14/22 - 11:02 am
Roche
Repare Therapeutics
licensing
J&J partner Aspen, with no orders for its COVID shot, warns low demand sends 'bad message'
Fierce Pharma
Wed, 05/18/22 - 10:49 am
JNJ
Aspen Pharmacare
licensing
South Africa
vaccines
COVID-19
Big pharma’s biggest spenders revealed
EP Vantage
Tue, 05/17/22 - 10:29 am
R&D
licensing
M&A
COVID-19
Big Pharma
Bristol Myers Squibb
JNJ
AbbVie
Sanofi
Merck
Novartis
Pfizer
AstraZeneca
Roche
GSK
Eli Lilly
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Upfront licensing costs hit a five year high
EP Vantage
Wed, 02/2/22 - 11:08 am
licensing
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
Biopharma’s ballooning licensing deal bill
EP Vantage
Tue, 07/27/21 - 04:26 pm
licensing
Biopharma’s big bet on cancer is laid bare
EP Vantage
Fri, 02/14/20 - 10:39 am
cancer
oncology
M&A
licensing
If you want blockbuster sales, buy them in
EP Vantage
Tue, 04/30/19 - 09:38 am
licensing
M&A
Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates
Fierce Pharma
Tue, 09/12/17 - 09:47 pm
Prevnar 13
vaccines
licensing
Pfizer
Oculus receives $5.1M licensing fee from More Pharma
Thu, 09/6/12 - 08:17 pm
Oculus Innovative Sciences
licensing
Top 20 biotech licensing deals in H1 2012
Fierce Biotech
Wed, 07/11/12 - 12:47 pm
Xenon
Virobay
Tolero Pharmaceuticals
Threshold Pharmaceuticals
Novartis
Merck KGaA
Merck
MannKind
licensing
Janssen
Isis Pharmaceuticals
Ironwood
Inhibrx Thrombogenics
GSK
Genmab
Genentech
Galapagos
Forma Therapeutics
Endocyte
Endo
Enanta
Celgene
Bristol-Myers Squibb
Boehringer Ingelheim
Bionomics
Biogen Idec
BioDelivery Sciences
AstraZeneca
Angiochem
AC Immune
Abbott Laboratories
LEO Pharma
Vical inks licensing deal with Astellas over vaccine for stem-cell transplant patients
Yahoo/AP
Fri, 07/15/11 - 01:07 am
Vical
licensing
Astellas
vaccines
stem cell transplant
GlaxoSmithKline licenses Amicus drug in $230M deal
Bizjournals.com
Fri, 10/29/10 - 11:38 am
Amicus Therapeutics
GSK
licensing
Amigal
Fabry's disease
Cypress Bioscience Licenses Alexza Pharmaceutical's Staccato(R) Nicotine
Yahoo
Thu, 08/26/10 - 09:28 am
Cypress Bioscience
licensing
Alexza
Staccato
smoking cessation
Biogen Idec licenses Lou Gehrig's disease drug
Yahoo/AP
Wed, 08/18/10 - 10:26 am
Biogen Idec
Lou Gehrig's disease
Knopp
licensing
Vectura Licenses Patents To GlaxoSmithKline
WSJ Online
Fri, 08/6/10 - 07:57 am
Vectura
licensing
GSK
GlaxoSmithKline licenses potential muscle disorder drugs from Five Prime in $139M deal
Yahoo/AP
Wed, 08/4/10 - 07:42 am
GSK
licensing
Five Prime

Pages